Autopsy report · NCT03236415

Comparative Response to Vascular Injury in Patients With Diabetes Mellitus: An OCT Study of BVS Versus Xience DES

“Global sales of the Absorb BVS halted effective September 14, 2017.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Na

Sponsor

Ottawa Heart Institute Research Corporation

Sponsor type

University, hospital or other

Conditions

Coronary Artery Disease; Diabetes Mellitus

Interventions

Xience Drug Eluting Stent; ABSORB Bioresorbable Vascular Scaffold

Participants

0

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.